Suppr超能文献

肝恶性肿瘤患者不同种族群体间的生存差异。

Survival disparities among racial groups with hepatic malignant tumors.

作者信息

Han Deng, Zhang Zhi-Yu, Deng Jin-Yan, Du Hong-Bo

机构信息

Division of Gastroenterology, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing 100700, China.

Beijing University of Chinese Medicine, Beijing 100105, China.

出版信息

World J Gastrointest Oncol. 2024 Jul 15;16(7):2999-3010. doi: 10.4251/wjgo.v16.i7.2999.

Abstract

BACKGROUND

Investigating the impact of race on the clinicopathologic characteristics and prognosis of hepatic malignant tumors represents a complex and significant area of research. Notably, distinct differences exist among various racial groups in terms of the clinical manifestations, pathologic features, and prognosis of hepatic malignant tumors.

AIM

To explore the effect of race on clinicopathologic features and prognosis of hepatic malignancies.

METHODS

Data from patients with hepatic malignancies diagnosed between 2000 and 2019 were collected from the Surveillance, Epidemiology, and End Results database and statistically analyzed.

RESULTS

This study included 123558 patients with hepatic malignant tumors, among whom 21078 (17.06%) were Asian, 14810 (11.99%) were Black, and 87670 (70.95%) were white. The median survival times for patients with hepatic malignant tumors of different races were 12.56, 7.70, and 9.35 months for Asian patients, Black patients, and white patients, respectively. The 3-year survival rates for Asian, Black, and white patients were 29%, 19%, and 21%, respectively, and the 5-year survival rates were 22%, 13%, and 15%, respectively. The Kruskal-Wallis test indicated a significant difference in the survival time of patients with hepatic malignant tumors between different races ( < 0.001). Univariate analysis revealed gender disparities in the prognosis among different ethnic groups (Asian: > 0.05; Black: < 0.001; White: < 0.05). Among Black patients, the prognosis was less affected by the degree of hepatic fibrosis than among Asian patients and white patients (Black patients: < 0.05; Asian patients: < 0.001; White patients: < 0.001). Significant differences were observed in the median survival time among patients with hepatic neuroendocrine tumors and hepatoblastomas during pathologic staging between races. Tumor number was inversely related to the prognosis. Cox regression analyses revealed that T stage, M stage, surgery, chemotherapy, alpha-fetoprotein, and tumor size independently influenced prognosis. Age was a specific independent prognostic factor for white patients. Among the tumor stages, N stage is a self-reliant prognostic element specific to white patients. Conversely, radiotherapy and liver fibrosis were not self-reliant prognostic factors for Black patients. Income alone did not independently influence the prognosis of Asian patients.

CONCLUSION

The prognosis of hepatic malignant tumors is better among Asian patients than among Black patients. The prognosis of hepatic malignant tumors among white patients is affected by multiple factors, including age and N stage.

摘要

背景

研究种族对肝脏恶性肿瘤临床病理特征及预后的影响是一个复杂且重要的研究领域。值得注意的是,不同种族群体在肝脏恶性肿瘤的临床表现、病理特征及预后方面存在明显差异。

目的

探讨种族对肝脏恶性肿瘤临床病理特征及预后的影响。

方法

收集2000年至2019年诊断为肝脏恶性肿瘤患者的数据,来自监测、流行病学和最终结果数据库,并进行统计分析。

结果

本研究纳入123558例肝脏恶性肿瘤患者,其中亚洲人21078例(17.06%),黑人14810例(11.99%),白人87670例(70.95%)。不同种族肝脏恶性肿瘤患者的中位生存时间分别为:亚洲患者12.56个月,黑人患者7.70个月,白人患者9.35个月。亚洲、黑人和白人患者的3年生存率分别为29%、19%和21%,5年生存率分别为22%、13%和15%。Kruskal-Wallis检验表明不同种族肝脏恶性肿瘤患者的生存时间存在显著差异(<0.001)。单因素分析显示不同种族群体预后存在性别差异(亚洲人:>0.05;黑人:<0.001;白人:<0.05)。在黑人患者中,肝纤维化程度对预后的影响小于亚洲患者和白人患者(黑人患者:<0.05;亚洲患者:<0.001;白人患者:<0.001)。不同种族间肝脏神经内分泌肿瘤和肝母细胞瘤患者病理分期时的中位生存时间存在显著差异。肿瘤数量与预后呈负相关。Cox回归分析显示,T分期、M分期、手术、化疗、甲胎蛋白和肿瘤大小独立影响预后。年龄是白人患者特有的独立预后因素。在肿瘤分期中,N分期是白人患者特有的独立预后因素。相反,放疗和肝纤维化不是黑人患者的独立预后因素。单独的收入并未独立影响亚洲患者的预后。

结论

亚洲患者肝脏恶性肿瘤的预后优于黑人患者。白人患者肝脏恶性肿瘤的预后受多种因素影响,包括年龄和N分期。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0e4b/11271794/93b2a59bf0a8/WJGO-16-2999-g001.jpg

相似文献

1
Survival disparities among racial groups with hepatic malignant tumors.
World J Gastrointest Oncol. 2024 Jul 15;16(7):2999-3010. doi: 10.4251/wjgo.v16.i7.2999.
2
Racial disparities in treatment and survival of patients with hepatocellular carcinoma in the United States.
Hepatobiliary Surg Nutr. 2016 Feb;5(1):43-52. doi: 10.3978/j.issn.2304-3881.2015.08.05.
3
Exploring the complexity and spectrum of racial/ethnic disparities in colon cancer management.
Int J Equity Health. 2023 Apr 14;22(1):68. doi: 10.1186/s12939-023-01883-w.
4
Racial and ethnic minorities in lower income brackets are associated with late-stage diagnosis of non-ocular melanoma.
Cancer Epidemiol. 2023 Dec;87:102489. doi: 10.1016/j.canep.2023.102489. Epub 2023 Nov 17.
5
Effects of Cancer Stage and Treatment Differences on Racial Disparities in Survival From Colon Cancer: A United States Population-Based Study.
Gastroenterology. 2016 May;150(5):1135-1146. doi: 10.1053/j.gastro.2016.01.030. Epub 2016 Feb 2.
6
Variation in Breast Cancer Subtype Incidence and Distribution by Race/Ethnicity in the United States From 2010 to 2015.
JAMA Netw Open. 2020 Oct 1;3(10):e2020303. doi: 10.1001/jamanetworkopen.2020.20303.
7
Who, where, when: Colorectal cancer disparities by race and ethnicity, subsite, and stage.
Cancer Med. 2023 Jul;12(13):14767-14780. doi: 10.1002/cam4.6105. Epub 2023 May 22.
8
Racial and ethnic characteristics and cancer-specific survival in Primary Malignant Cardiac Tumors.
Front Cardiovasc Med. 2022 Aug 25;9:961160. doi: 10.3389/fcvm.2022.961160. eCollection 2022.
10
Ethnic and racial differences in patients with Ewing sarcoma.
Cancer. 2010 Feb 15;116(4):983-8. doi: 10.1002/cncr.24865.

引用本文的文献

1
Primary hepatic carcinosarcoma: a case report with insights from retrospective analysis of clinical characteristics and prognostic factors.
Front Med (Lausanne). 2025 Jan 10;11:1470419. doi: 10.3389/fmed.2024.1470419. eCollection 2024.

本文引用的文献

2
Comprehensive Analysis to Identify the Encoded Gens of Sodium Channels as a Prognostic Biomarker in Hepatocellular Carcinoma.
Front Genet. 2022 Jan 21;12:802067. doi: 10.3389/fgene.2021.802067. eCollection 2021.
3
Racial and Ethnic Disparities in Barriers to Care in Patients with Hepatocellular Carcinoma.
Clin Gastroenterol Hepatol. 2023 Apr;21(4):1094-1096.e2. doi: 10.1016/j.cgh.2021.12.027. Epub 2021 Dec 26.
6
Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.
CA Cancer J Clin. 2021 May;71(3):209-249. doi: 10.3322/caac.21660. Epub 2021 Feb 4.
7
Chemerin suppresses hepatocellular carcinoma metastasis through CMKLR1-PTEN-Akt axis.
Br J Cancer. 2018 May;118(10):1337-1348. doi: 10.1038/s41416-018-0077-y. Epub 2018 May 2.
8
Disparities in liver cancer occurrence in the United States by race/ethnicity and state.
CA Cancer J Clin. 2017 Jul 8;67(4):273-289. doi: 10.3322/caac.21402. Epub 2017 Jun 6.
9
Racial/ethnic disparities in hepatocellular carcinoma treatment and survival in California, 1988-2012.
World J Gastroenterol. 2016 Oct 14;22(38):8584-8595. doi: 10.3748/wjg.v22.i38.8584.
10
The Burden of Cancer in Asian Americans: A Report of National Mortality Trends by Asian Ethnicity.
Cancer Epidemiol Biomarkers Prev. 2016 Oct;25(10):1371-1382. doi: 10.1158/1055-9965.EPI-16-0167.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验